Suchergebnisse - "Lobbezoo, Dorien J. A."

PubPharm (10)

1

Metastatic breast cancer:understanding prognosis and treatment patterns in real-life

Erschienen: Dissertation, Maastricht University, 2016

von Lobbezoo, D.

2

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients : A Study of the Southeast Netherlands Breast Cancer Consortium

enthalten in: The oncologist | 2015

von Seferina, S. | Lobbezoo, D. | de Boer, M. | +9

3

Real‐Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients : A Study of the Southeast Netherlands Breast Cancer Consortium

enthalten in: The oncologist | 2015

von Seferina, S. | Lobbezoo, D. | Boer, M. | +9

4

Combination of exemestane and everolimus may produce toxic side effects : a new treatment option for metastatic hormone-sensitive breast cancer

enthalten in: Nederlands tijdschrift voor geneeskunde | 2014

von Vincent, J. | de Boer, M. | Lobbezoo, D. | +2

5

Prognosis of metastatic breast cancer subtypes : the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

enthalten in: Breast cancer research and treatment | 2013

von Lobbezoo, D. | van Kampen, R. | Voogd, A. | +10

6

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

enthalten in: Breast cancer research and treatment | 2013

von Lobbezoo, D. | van Kampen, R. | Voogd, A. | +10

7

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

enthalten in: Breast cancer research and treatment | 2013

von Lobbezoo, D. | van Kampen, R. | Voogd, A. | +10

8

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

enthalten in: Breast cancer research and treatment | 2013

von Lobbezoo, D. | van Kampen, R. | Voogd, A. | +10

9

If there is no overall survival benefit in metastatic breast cancer : does it imply lack of efficacy? Taxanes as an example

enthalten in: Cancer treatment reviews | 2013

von Vriens, B. | Lobbezoo, D. | de Hoon, J. | +3

10

If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example

enthalten in: Cancer treatment reviews | 2013

von Vriens, B. | Lobbezoo, D. | de Hoon, J. | +3

1
[1]